This Article Free via Open Access: OA OA Abstract Figures Only Full Text (PDF) Supporting Information Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Morton, J. P. Articles by Lewis, B. C. Search for Related Content PubMed PubMed Citation Articles by Morton, J. P. Articles by Lewis, B. C. Social Bookmarking                What's this?

 Previous Article  | Table of Contents |  Next Article 

BIOLOGICAL SCIENCES / MEDICAL SCIENCES
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis

Jennifer P. Morton^*, Michelle E. Mongeau^*, David S. Klimstra, John P. Morris, Yie Chia Lee^*, Yoshiya Kawaguchi, Christopher V. E. Wright, Matthias Hebrok, and Brian C. Lewis^*,¶,||,**

*Program in Gene Function and Expression, ^¶Program in Molecular Medicine, and ^||Cancer Center, University of Massachusetts Medical School, Worcester, MA 01605; Department of Pathology, Memorial Sloan–Kettering Cancer Center, New York, NY 10021; Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143; and Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37235

Communicated by Harold E. Varmus, Memorial Sloan–Kettering Cancer Center, New York, NY, February 7, 2007 (received for review September 6, 2006)

	Abstract

Top Abstract Results Discussion Materials and Methods Acknowledgements References

 
Activation of sonic hedgehog (Shh) signaling occurs in the majority of pancreatic ductal adenocarcinomas. Here we investigate the mechanisms by which Shh contributes to pancreatic tumorigenesis. We find that Shh expression enhances proliferation of pancreatic duct epithelial cells, potentially through the transcriptional regulation of the cell cycle regulators cyclin D1 and p21. We further show that Shh protects pancreatic duct epithelial cells from apoptosis through the activation of phosphatidylinositol 3-kinase signaling and the stabilization of Bcl-2 and Bcl-X_L. Significantly, Shh also cooperates with activated K-Ras to promote pancreatic tumor development. Finally, Shh signaling enhances K-Ras-induced pancreatic tumorigenesis by reducing the dependence of tumor cells on the sustained activation of the MAPK and phosphatidylinositol 3-kinase/Akt/mTOR signaling pathways. Thus, our data suggest that Shh signaling contributes to tumor initiation in the pancreas through at least two mechanisms and additionally enhances tumor cell resistance to therapeutic intervention. Collectively, our findings demonstrate crucial roles for Shh signaling in multiple stages of pancreatic carcinogenesis.

K-ras | mouse model | pancreatic cancer | Shh

Hedgehog ligands bind to their receptors and activate a signaling cascade that culminates in the nuclear translocation of Gli transcription factors and the regulation of target genes (4–6). Interestingly, sonic hedgehog (Shh) is excluded from the developing pancreas, as well as the mature organ (7), yet is activated in early PanIN lesions, with increasing levels as lesions progress to invasive PDAC (8, 9). Further, ectopic expression of Shh under the control of the Pdx-1 promoter, active in pancreas progenitor cells, induces intestinal metaplasia in the pancreas accompanied by mutations in Kras (8). Significantly, inhibition of hedgehog signaling blocks proliferation and induces apoptosis, in culture and s.c. xenografts, in a subset of these cell lines (8, 9). Thus, the evidence suggests that activated Shh signaling is a critical early mediator of pancreatic cancer development.

Yet little is understood about the mechanisms by which Shh signaling contributes to this disease. We report here the consequences of Shh expression on the proliferation and survival of pancreatic duct epithelial cells (PDECs). We demonstrate that Shh expression enhances tumor initiation and growth and reduces tumor cell death after therapeutic intervention. These findings reveal critical roles for Shh signaling in pancreatic tumor initiation, growth, and survival, and greatly enhance our understanding of the role of Shh in pancreatic carcinoma.

	Results

Top Abstract Results Discussion Materials and Methods Acknowledgements References

 
Targeting the Pancreatic Duct Epithelium. To target the pancreatic duct epithelium, we generated transgenic mice in which expression of the receptor for avian leukosis virus subgroup A (ALV-A), TVA [encoded by the quail ALV-A susceptibility locus tumor virus A (tv-a)], is regulated by the keratin 19 promoter and enhancer elements (K19-tv-a mice) (10–13). Immunofluorescent staining of pancreas tissue sections demonstrated the presence of TVA specifically within the duct epithelium (B.C.L. and H. Varmus, unpublished data). We found that PDECs isolated from transgenic (but not nontransgenic) animals are susceptible to infection by ALV-A-based RCAS viruses (Fig. 1A, data not shown).

View larger version (39K): [in this window] [in a new window]   Fig. 1. Shh expression and signaling in PDECs. (A) RCAS-GFP-infected PDECs in culture. (Left) Phase contrast image. (Right) Fluorescent image. (B) Formation of duct-like structures by GFP-expressing Trp53, Ink4a/Arf null PDECs embedded in matrigel. (C) Detection of Shh expression in RCAS-Shh- and RCAS-GFP-infected PDECs by immunoblotting with an anti-myc monoclonal antibody. Tumor suppressor genotypes are indicated. -actin serves as a control. (D) RT-PCR analysis of Shh pathway components in RCAS-Shh- and RCAS-GFP-infected PDECs. -actin serves as a control. w.t., wild type.

Shh Enhances Proliferation of PDECs. To identify the effect of active Shh signaling on PDECs, we infected cultured TVA-positive PDECs with RCAS viruses encoding a myc epitope-tagged Shh molecule or GFP as a control (19). Expression of the introduced Shh was confirmed by immunoblotting protein lysates with an anti-c-myc antibody (Fig. 1C). RT-PCR analysis of the hedgehog pathway components Gli1 and ptch1, previously described hedgehog targets (20), demonstrated activation of hedgehog signaling (Fig. 1D). Interestingly, Smo mRNA levels were also elevated in Shh-expressing cells (Fig. 1D).

We next determined whether active Shh signaling stimulates the proliferation of PDECs. Shh- and GFP-expressing PDECs were plated at equal numbers, and cells were harvested and counted after 5, 10, and 15 days. We observed that Shh stimulates the proliferation of PDECs relative to their GFP-expressing counterparts, and that this effect is independent of tumor suppressor gene status (Fig. 2A).

View larger version (59K): [in this window] [in a new window]   Fig. 2. Shh enhances the proliferation of PDECs. (A) Cell numbers for Shh- or GFP-expressing PDECs of the indicated tumor suppressor genotypes at the indicated times after plating. Dotted lines, Shh-expressing PDECs; solid lines, GFP-expressing PDECs. Results are representative of at least two experiments. (B) RT-PCR analysis of cell cycle-related transcripts in RCAS-Shh- and RCAS-GFP-infected PDECs. -actin serves as a control. (C) Immunoblot analysis of cell cycle- and Ras-regulated signaling molecules in RCAS-Shh- and RCAS-GFP-infected PDECs. -actin serves as a control. w.t., wild type.

Activation of the MAPK and phosphatidylinositol 3-kinase (PI3-kinase) signaling pathways is commonly found in PDAC (23). Immunoblot analysis of lysates from serum-starved PDECs showed increased phosphorylation of Akt, indicative of pathway activation, in all Shh-expressing cells relative to GFP-expressing cells, and increased phosphorylation of Erk1/2, with a more pronounced effect in cells deficient at one or more tumor suppressor loci (Fig. 2C). Interestingly, expression of an activated Gli1 molecule (24) in PDECs did not stimulate these pathways (data not shown).

Flow-cytometry analysis showed that 73.4% of GFP-expressing PDECs are in G₁ with 18.9% in S-phase, whereas Shh expression increases the S-phase fraction to 27.1% and reduces the G₁ fraction to 59.1%. Inhibition of PI3-kinase with LY294002 or MAPK signaling with PD98059 reduces the S-phase fraction to 21.6% and 17.6%, respectively, and increases the G₁ fraction to 68.7% and 68.2%, respectively, suggesting that the activation of these pathways is required for Shh-induced proliferation. Collectively, these data indicate that Shh may stimulate proliferation of PDECs through the regulation of multiple molecules.

Shh Enhances Survival of PDECs. To determine whether Shh expression in PDECs confers resistance to apoptotic stimuli, we exposed PDECs to the cytotoxic agent cycloheximide (CHX) (25, 26), recently shown to induce apoptosis in pancreatic cancer cell lines (27). We found that Shh expression enhances survival after 24 or 48 h of exposure to 100 µM CHX independent of tumor suppressor status, as determined by trypan blue exclusion (Fig. 3A). We also found that Shh expression protects against death induced by UV irradiation (data not shown). Elevated levels of the cleaved, or active, form of caspase 3 were detected in GFP-expressing but not Shh-expressing PDECs, confirming the CHX-induced death as apoptosis (Fig. 3B). The CHX-induced apoptosis depends on Fas, caspase 8, and caspase 3 because inhibition of these molecules blocks cell death after CHX exposure (data not shown). Thus, Shh protects PDECs from Fas-dependent apoptosis, consistent with findings in other cell types (28).

View larger version (43K): [in this window] [in a new window]   Fig. 3. Shh promotes the survival of PDECs. (A) Viability of PDECs of the indicated tumor suppressor genotypes after treatment with a 100 µM concentration of CHX or vehicle as measured by trypan blue exclusion. Shaded bars, Shh-expressing PDECs; open bars, GFP-expressing PDECs. Results are representative of at least two experiments. (B) Immunoblot analysis of cleaved and uncleaved caspase 3 in protein lysates from RCAS-GFP- and RCAS-Shh-infected Ink4a/Arf, Trp53 null PDECs before and after a 24-hour treatment with 100 µM CHX. -actin serves as a control. (C) Immunoblot analysis of Bcl-2 family members in protein lysates from RCAS-GFP- and RCAS-Shh-infected Ink4a/Arf, Trp53 PDECs treated with a 100 µM concentration of CHX or vehicle. -actin serves as a control. (D) RT-PCR demonstrating Bcl-XL mRNA levels in untreated and CHX-treated Ink4a/Arf, Trp53 null PDECs. -actin serves as a control. (E) Viability of Ink4a/Arf, Trp53 null PDECs after treatment with CHX and Bcl-2, MAPK, and PI3-kinase inhibitors. Shaded bars, Shh-expressing PDECs; open bars, GFP-expressing PDECs. Results are representative of two experiments. *, P < 0.01 for CHX + inhibitors compared with CHX alone.

Shh Cooperates with K-Ras in Pancreatic Tumorigenesis. To determine whether Shh expression within the pancreas results in tumor formation, we used Shh-expressing PDECs in an orthotopic transplant model; 2 x 10⁶ wild-type, Ink4a/Arf null, Trp53 null, and Ink4a/Arf, Trp53 null PDECs expressing either Shh or GFP were implanted into the pancreata of eight age-matched nude mice, and animals were monitored for 4 months. No grossly visible tumors developed; however, serial sectioning of harvested pancreata identified lesions with the features of PDAC precursor lesions in four of seven animals implanted with Trp53, Ink4a/Arf null Shh-expressing cells and two of three animals implanted with Trp53 null Shh-expressing cells [see supporting information (SI) Fig. 6]. All lesions displayed enhanced proliferation as denoted by Ki67 staining, and all lesions stained positive for Pdx1 (SI Fig. 6). No animals transplanted with Ink4a/Arf null or wild-type cells developed pancreatic lesions. These findings suggest that activation of the hedgehog pathway might initiate pancreatic tumorigenesis.

Activating KRAS2 mutations are present in 90% of all ductal adenocarcinomas. We found that Ink4a/Arf, Trp53 null PDECs infected with RCAS viruses encoding a FLAG epitope-tagged activated K-RasG₁2D molecule (hereafter simply denoted as K-Ras) proliferate faster than GFP controls (Fig. 4A). Significantly, when PDECs from Ink4a/Arf, Trp53 null pancreata are infected with both Shh- and K-Ras-bearing RCAS viruses, proliferation is enhanced when compared with PDECs expressing either Shh or K-Ras alone (Fig. 4A). We also found that activated Ras signaling protects PDECs from death when challenged with apoptotic stimuli (data not shown).

View larger version (61K): [in this window] [in a new window]   Fig. 4. Cooperative interaction between Shh and activated K-Ras. (A) Proliferation curves for Ink4a/Arf, Trp53 null PDECs expressing GFP, Shh, K-Ras, or both Shh and K-Ras. (B) Cystic ductal lesion induced after orthotopic transplantation of K-Ras- and Shh-expressing Trp53 null PDECs. Note abundant reactive stroma. (C) H&E-stained tissue section illustrating the histology of tumors induced after orthotopic transplantation of Ink4a/Arf, Trp53 null PDECs expressing both Shh and activated K-Ras. Tumors are mostly undifferentiated (D), with regions of ductal differentiation (box in C, and E). (F) RT-PCR analysis of Shh pathway components in tumors induced after orthotopic transplantation of RCAS-k-ras-infected PDECs (R1–R6) or RCAS-Shh- and RCAS-k-ras-infected PDECs (RS1–RS7). Tumors R1–R3 and RS1–RS3 lack Ink4a/Arf. Tumors R4–R6 and RS4–RS7 lack Trp53 and Ink4a/Arf. -actin serves as a control.

Transplantation of tumor suppressor wild-type PDECs did not result in tumor formation. Cystic ductal tumors were identified in 11 of 15 mice transplanted with 0.5, 1, or 2 x 10⁶ Trp53 null cells expressing Shh and K-Ras (Table 1 and Fig. 4B). By contrast, only 5 of 16 animals transplanted with Trp53 null cells expressing K-Ras had any pancreatic lesions; by histology, three of these lesions resembled precursor PanIN lesions (data not shown). Further, no microscopic lesions were identified in non-tumor-bearing pancreata, indicating that Shh enhances tumor initiation in Trp53 null cells. In addition, the tumors induced by the combination of Shh and K-Ras were of a significantly larger size than those induced by K-Ras alone, indicating an additional role for Shh in tumor growth (Table 1).

Histologically, the tumors induced by K-Ras, or Shh and K-Ras, in the Ink4a/Arf or Ink4a/Arf, Trp53 null backgrounds were undifferentiated carcinomas. The majority of the tumor mass had a sarcomatoid appearance, with regions of glandular differentiation (Fig. 4 C–E). The expression of Shh did not impact the differentiation status of the tumor. Immunoblotting of protein lysates from tumors induced by K-Ras, or K-Ras and Shh, identified the presence of the inducing oncoproteins in all tumors (SI Fig. 7A). Further, RT-PCR for the hedgehog pathway components ptch, smo, and Gli1 demonstrated elevated expression of each of these components in Shh-expressing tumors relative to those induced by K-Ras alone (Fig. 4F). Thus, collectively, our findings suggest that Shh cooperates with activated K-Ras in the development and growth of pancreatic tumors.

To further characterize these tumor cells, we established cell lines from four tumors expressing K-Ras only and lacking both Trp53 and Ink4a/Arf and from seven tumors expressing Shh and K-Ras and lacking Ink4a/Arf or Trp53 and Ink4a/Arf. Immunocytochemistry revealed that all cell lines were positive for K-Ras and Shh where expected and contained cells positive for keratin 8 and Pdx1, confirming their origin as PDECs (SI Fig. 7B).

We next analyzed the response of the tumor cell lines to the inhibition of downstream Ras signaling pathways by treating them with either 25 µM PD98059 to inhibit the MAPK pathway or 20 µM LY294002 to inhibit PI3-kinase signaling. Increased cell death did not occur in any cell line after treatment, as measured by trypan blue exclusion (data not shown). Pathway inhibition at 72 h was equivalent in all cell lines as shown by immunoblotting for phosphorylated Erk or phosphorylated Akt (Fig. 5 A and B). We observed that, although cell lines expressing K-Ras alone failed to proliferate in the presence of these inhibitors, cells expressing both Shh and K-Ras continued to proliferate in the presence of these compounds (Fig. 5 A and B). Similar findings were observed after treatment with rapamycin, which inhibits mTOR, and simultaneous treatment with rapamycin and PD98059 failed to completely inhibit the growth of cells expressing K-Ras and Shh, although there was an additive effect on cell proliferation (data not shown). Thus, these data indicate that Shh signaling in pancreatic cancer cells can reduce the requirement for sustained Ras signaling.

View larger version (39K): [in this window] [in a new window]   Fig. 5. Shh and K-Ras in therapeutic intervention. Proliferation curves of untreated cell lines (dashed lines) or cells treated with specific pathway inhibitors (solid lines) after treatment with the MAPK inhibitor PD98059 (PD) (A), the PI3-kinase inhibitor LY294002 (LY) (B), the smoothened antagonist cyclopamine (CYC) (C), or LY294002 and cyclopamine (D). Immunoblotting of lysates from treated cells for phospho-ERK and phospho-Akt, and RT-PCR for Gli1, confirms comparable pathway inhibition in all cell lines.

	Discussion

Top Abstract Results Discussion Materials and Methods Acknowledgements References

 
Previous studies have suggested a role for Shh signaling in pancreatic carcinogenesis (8, 9, 31). Yet, before our study, the mechanisms by which hedgehog signaling contributes to pancreatic tumor initiation and progression were unknown. We have now demonstrated that ectopic expression of Shh in cultured PDECs enhances their proliferation in a MAPK- and PI3-kinase-dependent manner. We additionally showed that Shh protects PDECs from apoptotic stimuli partly through the posttranscriptional regulation of Bcl-2 and Bcl-X_L. Significantly, activation of the PI3-kinase pathway is required for Shh-induced stabilization of Bcl-2 and Bcl-X_L, although the mechanisms through which this occurs are unknown. Thus, activated hedgehog signaling induces two of the "hallmarks of cancer" in PDECs, the presumptive target cells for PDAC, and in this way may contribute to the initiation of pancreatic tumorigenesis (32).

It remains unclear how Shh signaling activates the MAPK and PI3-kinase pathways. Consistent with our recent findings, analysis of PDECs expressing an activated Gli1 molecule demonstrated that the stimulation of these pathways occurs, at least in part, through Gli-independent mechanisms (31). Given the functional redundancy of Gli transcription factors, we were unable to ascertain whether they are required for Shh-mediated MAPK and PI3-kinase stimulation. Analysis of the expression levels of the Her2 and EGFR tyrosine kinases, which are potent activators of these pathways and are frequently overexpressed in early PanIN lesions, failed to identify elevated expression in Shh-expressing cells (33). Neither does it involve activating mutations in k-ras, as suggested by previous work (8), a result consistent with our recent findings with an activated Gli2 allele (31).

Orthotopic transplantation of PDECs with constitutive activation of Shh signaling led to the formation of early ductal pancreatic lesions. These lesions displayed many features of precursor PanIN lesions (3, 23). However, the extent of these features was considered insufficient by an experienced pathologist (D.S.K.) for definitive classification as mouse PanIN based upon the criteria established by the Penn Workshop (34). Interestingly, while these lesions formed, they failed to advance to frank tumors during the timeframe of our experiments. However, we did find that Shh enhanced tumor initiation by an activated K-Ras molecule and accelerated tumor growth, consistent with cooperation between Shh and IGF signaling in other model systems (35). Thus, our results collectively demonstrate a role for the Shh pathway in PDAC initiation and progression and are consistent with the activation of the pathway in early PanIN lesions and the sustained activation of the pathway during tumor progression (8, 9).

Our findings with Shh-expressing PDECs also provide an interesting contrast with activated K-Ras signaling in these cells. Transplantation of RCAS-k-ras-infected PDECs lacking either Ink4a/Arf or Ink4a/Arf and Trp53 led to the development of undifferentiated carcinomas within 60 days of transplant. Yet our cell culture studies demonstrated that in Ink4a/Arf, Trp53 null PDECs, Shh stimulated proliferation to a similar extent as an activated K-Ras molecule. We did find, however, that K-Ras provided a slightly more robust survival advantage to CHX-treated PDECs. The enhanced ability of K-Ras to transform PDECs may reflect this enhanced survival advantage or, alternatively, the activation of the Ral signaling pathway, which has been shown in other experimental systems to mediate, in large part, the transforming properties of activated Ras proteins (36, 37). Our results further underscored the functional significance of activating KRAS gene mutations as critical initiating events in pancreatic tumorigenesis; indeed, previously generated mouse models demonstrated that activation of K-Ras is sufficient to induce pancreatic tumors in vivo (38, 39). Detailed comparisons between PDECs expressing either Shh or K-Ras may therefore provide critical clues to the mechanisms underlying pancreatic cancer development.

Interestingly, we also found that Shh signaling reduced tumor cell dependence on the initiating oncogenic lesion. All four cell lines expressing K-Ras alone, and lacking Trp53 and Ink4a/Arf, remained sensitive to inhibition of the MAPK and PI3-kinase signaling pathways, demonstrating their continued requirement for tumor cell proliferation. This result contradicts previously published findings suggesting that activation of the PI3-kinase pathway was sufficient for tumor maintenance and may reflect either cell type or species differences, or the methods used to induce cell transformation (40). Yet all cell lines that express both K-Ras and Shh, including those that retain wild-type Trp53 alleles, continued to proliferate despite inhibition of these signaling pathways. Thus, constitutive Shh pathway activation reduced the dependence of tumor cells on activated K-Ras. This finding is significant because it predicts that a subset of PDAC, those with high levels of constitutively active Shh signaling, will be resistant to treatment with therapeutics that target Ras-regulated signaling pathways, several of which are currently in development and clinical trials.

We also observed that tumor cells expressing both Shh and K-Ras continued to proliferate when Shh signaling was inhibited. However, simultaneous inhibition of the Shh and PI3-kinase pathways blocked cell proliferation. Thus, Shh and K-Ras appeared to cooperate by providing independent signals that regulated tumor cell proliferation, although the precise mechanisms of this cooperation remain unclear. Analysis of the genomic, epigenetic, and gene expression profiles of the cell lines generated during our studies may shed light on potential collaborative changes involved in these processes.

Thus, our studies indicated a role for Shh in pancreatic tumor initiation and growth and also highlighted the potential impact of this pathway on therapeutic interventions in this malignancy.

	Materials and Methods

Top Abstract Results Discussion Materials and Methods Acknowledgements References

 
Transgenic Mice and Animal Care. The generation of keratin-19-tv-a transgenic mice is described elsewhere. The Ink4a/Arf^lox/lox, Trp53^lox/lox, and Ptf1a-Cre strains have been previously described (15–17). Athymic nude mice were purchased from Charles River Laboratories (Wilmington, MA). Animals were kept in specific pathogen-free housing with abundant food and water under guidelines approved by the University of Massachusetts Medical School Institutional Animal Care and Use Committee.

Isolation, Culture, and Infection of Mouse PDECs. Isolation and culture of mouse PDECs were performed as previously described (18). The RCAS-GFP and RCAS-Shh vectors have been described previously (41–43). Details on the construction of the RCAS-k-ras vector are provided in SI Methods. For proliferation assays, 10⁵ cells were plated per well and counted at 5-day intervals. All experiments were performed in duplicate. For apoptosis assays, 10⁶ cells were plated per well and treated with 100 µM CHX for 24 or 48 h. For pathway interrogation, cells were incubated with indicated inhibitors for 1 h before CHX treatment.

Immunoblotting. Protein lysates were transferred to PVDF membranes (Hybond), and immunoblotting was performed as described (14). The complete list of primary antibodies and dilutions is provided in SI Table 2.

RT-PCR. A total of 0.5 µg of purified total RNA was used for RT-PCR by using the SuperScript III One-Step RT-PCR kit (Invitrogen, Carlsbad, CA). Amplification parameters and primer pair sequences are provided in SI Table 4.

Orthotopic Implantation of PDECs. Mice were anesthetized by i.p. injection of a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine (Henry Schein Inc., Melville, NY) and 10 µl of the appropriate PDECs resuspended in matrigel injected into the pancreata of nude mice as described (44).

Immunostaining. Immunostaining was performed as previously described (14). Primary antibody dilutions are listed in SI Table 3.

Culture and Treatment of Tumor Cell Lines. Cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS and antibiotics in a humidified incubator at 37°C (5% CO₂). Cell lines were plated at a density of 1 x 10⁵ cells per well; allowed to adhere; treated with 25 µM PD98059, 20 µM LY294002, 10 µM cyclopamine, or vehicle; and counted at 24, 48, and 72 h after treatment.

	Acknowledgements

Top Abstract Results Discussion Materials and Methods Acknowledgements References

 
The authors thank Paul Krimpenfort and Anton Berns (Netherlands Cancer Institute, Amsterdam, The Netherlands) for Trp53 and Ink4a/Arf conditional mutant mice; Dan Fults (University of Utah, Salt Lake City, UT) for RCAS-Shh DF1 producer cells; Anil Rustgi and Therese Deramaudt (University of Pennsylvania, Philadelphia, PA) for assistance with PDEC isolation; Eric Sandgren (University of Wisconsin, Madison, WI) for keratin 19 promoter and enhancer constructs; Michael Green (University of Massachusetts, Worcester, MA) for apoptosis reagents; and Lucio Castilla and members of the Lewis and Hebrok laboratories for critical reading of the manuscript and helpful discussions. This work was supported by the Pancreatic Cancer Alliance, a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, American Cancer Society Grant IRG93–033, the Worcester Foundation for Biomedical Research (B.C.L), and National Institutes of Health Grant RO1 CA112537 (to M.H.).

	Footnotes

 

Abbreviations: CHX, cycloheximide; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; PDECs, pancreatic duct epithelial cells.

**To whom correspondence should be addressed. E-mail: Brian.Lewis{at}umassmed.edu

Freely available online through the PNAS open access option.

Author contributions: J. P. Morton, J. P. Morris, M.H., and B.C.L. designed research; J. P. Morton, M.E.M., J. P. Morris, and Y.C.L. performed research; Y.K. and C.V.E.W. contributed new reagents/analytic tools; J. P. Morton, D.S.K., M.H., and B.C.L. analyzed data; and J. P. Morton and B.C.L. wrote the paper.

The authors declare no conflict of interest.

This article contains supporting information online at www.pnas.org/cgi/content/full/0701158104/DC1.

© 2007 by The National Academy of Sciences of the USA

	References

Top Abstract Results Discussion Materials and Methods Acknowledgements References

 

1. Jemal, A, Murray, T, Samuels, A, Ghafoor, A, Ward, E & Thun, MJ. (2003) CA Cancer J Clin 53, 5–26.[Abstract/Free Full Text]
2. Warshaw, AL & Fernandez-del Castillo, C. (1992) N Engl J Med 326, 455–465.[ISI][Medline]
3. Hruban, RH, Goggins, M, Parsons, J & Kern, SE. (2000) Clin Cancer Res 6, 2969–2972.[Free Full Text]
4. Freeman, M. (2000) Nature 408, 313–319.[CrossRef][Medline]
5. Pasca di Magliano, M & Hebrok, M. (2003) Nat Rev Cancer 3, 903–911.[CrossRef][ISI][Medline]
6. Cohen, MM Jr. (2003) Am J Med Genet A 123, 5–28.[Medline]
7. Kim, SK & Hebrok, M. (2001) Genes Dev 15, 111–127.[Free Full Text]
8. Thayer, SP, di Magliano, MP, Heiser, PW, Nielsen, CM, Roberts, DJ, Lauwers, GY, Qi, YP, Gysin, S, Fernandez-del Castillo, C & Yajnik, V, et al. (2003) Nature 425, 851–856.[CrossRef][Medline]
9. Berman, DM, Karhadkar, SS, Maitra, A, Montes De Oca, R, Gerstenblith, MR, Briggs, K, Parker, AR, Shimada, Y, Eshleman, JR, Watkins, DN & Beachy, PA. (2003) Nature 425, 846–851.[CrossRef][Medline]
10. Bader, BL & Franke, WW. (1990) Differentiation 45, 109–118.[CrossRef][ISI][Medline]
11. Hu, L & Gudas, LJ. (1994) J Biol Chem 269, 183–191.[Abstract/Free Full Text]
12. Grippo, PJ & Sandgren, EP. (2000) Am J Pathol 157, 805–813.[Abstract/Free Full Text]
13. Orsulic, S. (2002) Mamm Genome 13, 543–547.[CrossRef][ISI][Medline]
14. Lewis, BC, Klimstra, DS & Varmus, HE. (2003) Genes Dev 17, 3127–3138.[Abstract/Free Full Text]
15. Jonkers, J, Meuwissen, R, van der Gulden, H, Peterse, H, van der Valk, M & Berns, A. (2001) Nat Genet 29, 418–425.[CrossRef][ISI][Medline]
16. Kawaguchi, Y, Cooper, B, Gannon, M, Ray, M, MacDonald, RJ & Wright, CV. (2002) Nat Genet 32, 128–134.[CrossRef][ISI][Medline]
17. Krimpenfort, P, Quon, KC, Mooi, WJ, Loonstra, A & Berns, A. (2001) Nature 413, 83–86.[CrossRef][Medline]
18. Schreiber, FS, Deramaudt, TB, Brunner, TB, Boretti, MI, Gooch, KJ, Stoffers, DA, Bernhard, EJ & Rustgi, AK. (2004) Gastroenterology 127, 250–260.[CrossRef][ISI]
19. Rao, G, Pedone, CA, Coffin, CM, Holland, EC & Fults, DW. (2003) Neoplasia 5, 198–204.[ISI][Medline]
20. Kalderon, D. (2000) Cell 103, 371–374.[CrossRef][ISI][Medline]
21. Kenney, AM & Rowitch, DH. (2000) Mol Cell Biol 20, 9055–9067.[Abstract/Free Full Text]
22. Ohta, M, Tateishi, K, Kanai, F, Watabe, H, Kondo, S, Guleng, B, Tanaka, Y, Asaoka, Y, Jazag, A & Imamura, J, et al. (2005) Cancer Res 65, 10822–10829.[Abstract/Free Full Text]
23. Hezel, AF, Kimmelman, AC, Stanger, BZ, Bardeesy, N & Depinho, RA. (2006) Genes Dev 20, 1218–1249.[Abstract/Free Full Text]
24. Browd, SR, Kenney, AM, Gottfried, ON, Yoon, JW, Walterhouse, D, Pedone, CA & Fults, DW. (2006) Cancer Res 66, 2666–2672.[Abstract/Free Full Text]
25. Gong, J, Li, X & Darzynkiewicz, Z. (1993) J Cell Physiol 157, 263–270.[CrossRef][ISI][Medline]
26. Collins, RJ, Harmon, BV, Souvlis, T, Pope, JH & Kerr, JF. (1991) Br J Cancer 64, 518–522.[ISI][Medline]
27. Koehler, JA & Drucker, DJ. (2006) Diabetes 55, 1369–1379.[Abstract/Free Full Text]
28. Sacedon, R, Diez, B, Nunez, V, Hernandez-Lopez, C, Gutierrez-Frias, C, Cejalvo, T, Outram, SV, Crompton, T, Zapata, AG, Vicente, A & Varas, A. (2005) J Immunol 174, 1456–1461.[Abstract/Free Full Text]
29. Kuwana, T & Newmeyer, DD. (2003) Curr Opin Cell Biol 15, 691–699.[CrossRef][ISI][Medline]
30. Hingorani, SR, Wang, L, Multani, AS, Combs, C, Deramaudt, TB, Hruban, RH, Rustgi, AK, Chang, S & Tuveson, DA. (2005) Cancer Cell 7, 469–483.[CrossRef][ISI][Medline]
31. Pasca di Magliano, M, Sekine, S, Ermilov, A, Ferris, J, Dlugosz, AA & Hebrok, M. (2006) Genes Dev 20, 3161–3173.[Abstract/Free Full Text]
32. Hanahan, D & Weinberg, RA. (2000) Cell 100, 57–70.[CrossRef][ISI][Medline]
33. Bardeesy, N & DePinho, RA. (2002) Nat Rev Cancer 2, 897–909.[CrossRef][ISI][Medline]
34. Hruban, RH, Rustgi, AK, Brentnall, TA, Tempero, MA, Wright, CV & Tuveson, DA. (2006) Cancer Res 66, 14–17.[Abstract/Free Full Text]
35. Rao, G, Pedone, CA, Valle, LD, Reiss, K, Holland, EC & Fults, DW. (2004) Oncogene 23, 6156–6162.[CrossRef][ISI][Medline]
36. Hamad, NM, Elconin, JH, Karnoub, AE, Bai, W, Rich, JN, Abraham, RT, Der, CJ & Counter, CM. (2002) Genes Dev 16, 2045–2057.[Abstract/Free Full Text]
37. Lim, KH, Baines, AT, Fiordalisi, JJ, Shipitsin, M, Feig, LA, Cox, AD, Der, CJ & Counter, CM. (2005) Cancer Cell 7, 533–545.[CrossRef][ISI][Medline]
38. Aguirre, AJ, Bardeesy, N, Sinha, M, Lopez, L, Tuveson, DA, Horner, J, Redston, MS & DePinho, RA. (2003) Genes Dev 17, 3112–3126.[Abstract/Free Full Text]
39. Hingorani, SR, Petricoin, EF, Maitra, A, Rajapakse, V, King, C, Jacobetz, MA, Ross, S, Conrads, TP, Veenstra, TD & Hitt, BA, et al. (2003) Cancer Cell 4, 437–450.[CrossRef][ISI][Medline]
40. Lim, KH & Counter, CM. (2005) Cancer Cell 8, 381–392.[CrossRef][ISI][Medline]
41. Holland, EC. (2000) Toxicol Pathol 28, 171–177.[Abstract/Free Full Text]
42. Fults, D, Pedone, C, Dai, C & Holland, EC. (2002) Neoplasia 4, 32–39.[CrossRef][ISI][Medline]
43. Orsulic, S, Li, Y, Soslow, RA, Vitale-Cross, LA, Gutkind, JS & Varmus, HE. (2002) Cancer Cell 1, 53–62.[CrossRef][ISI][Medline]
44. Mohammad, RM, Al-Katib, A, Pettit, GR, Vaitkevicius, VK, Joshi, U, Adsay, V, Majumdar, AP & Sarkar, FH. (1998) Clin Cancer Res 4, 887–894.[Abstract]

CiteULike

Complore

Connotea

Del.icio.us

Digg

This article has been cited by other articles in HighWire Press-hosted journals:

				R. V. Sillitoe and M. W. Vogel Desire, Disease, and the Origins of the Dopaminergic System Schizophr Bull, March 1, 2008; 34(2): 212 - 219. [Abstract] [Full Text] [PDF]

				R. K. Lindemann Stroma-Initiated Hedgehog Signaling Takes Center Stage in B-Cell Lymphoma Cancer Res., February 15, 2008; 68(4): 961 - 964. [Abstract] [Full Text] [PDF]

				C. A. Parkin and P. W. Ingham The Adventures of Sonic Hedgehog in Development and Repair. I. Hedgehog signaling in gastrointestinal development and disease Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G363 - G367. [Abstract] [Full Text] [PDF]

This Article Free via Open Access: OA OA Abstract Figures Only Full Text (PDF) Supporting Information Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Morton, J. P. Articles by Lewis, B. C. Search for Related Content PubMed PubMed Citation Articles by Morton, J. P. Articles by Lewis, B. C. Social Bookmarking                What's this?

Current Issue | Archives | Online Submission | Info for Authors | Editorial Board | About Subscribe | Advertise | Contact | Site Map Copyright © 2007 by the National Academy of Sciences